PUBLISHER: GlobalData | PRODUCT CODE: 1746738
PUBLISHER: GlobalData | PRODUCT CODE: 1746738
Endometriosis: Epidemiology Forecast to 2034
Endometriosis is a chronic disease, and is defined as the presence of functional endometrial mucosa outside the uterine cavity, often in the pelvis, but also more rarely in locations such as the pericardium, pleura cavity, and even in the brain tissue (World Health Organization, 2025). It is one of the most common benign gynecological diseases in pre-menopausal women, and affects roughly 10-15% of reproductive age women and girls globally (World Health Organization, 2025). Normally, endometrial tissue or endometrium forms the lining inside the uterus, which thickens, breaks down, and bleeds with each menstrual cycle. However, in women with endometriosis, endometrium grows in places outside the uterus, and it does not leave the body (Mayo Clinic, 2024).
In the 7MM, the diagnosed incident cases of endometriosis are expected to decrease from 382,224 cases in 2024 to 381,348 cases in 2034, at a negative annual growth rate (AGR) of 0.02%. In 2034, the US will have the highest number of diagnosed incident cases of endometriosis in the 7MM, with 236,327 cases, whereas Spain will have the fewest diagnosed incident cases of endometriosis with 12,625 cases. GlobalData epidemiologists attribute the decline in the diagnosed incident cases of endometriosis to changes in population dynamics, as well as the incidence rates in each market over the forecast period.
In the 7MM, the diagnosed prevalent cases of endometriosis are expected to increase from 2,769,483 cases in 2024 to 2,795,334 cases in 2034, at an AGR of 0.09%. In 2034, the US will have the highest number of diagnosed prevalent cases of endometriosis in the 7MM, with 1,507,985 cases, whereas Japan will have the fewest diagnosed prevalent cases of endometriosis with 86,850 cases. GlobalData epidemiologists attribute the increase in the diagnosed prevalent cases of endometriosis to changes in population dynamics and the diagnosed prevalence rate in each market over the forecast period.
Scope
- This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for endometriosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed incident cases and diagnosed prevalent cases of endometriosis. The diagnosed incident cases and the diagnosed prevalent cases of endometriosis are segmented by age (12-17 years, 18-29 years, 30-39 years, 40-49 years, and 50-54 years) among women.
- The report also includes the diagnosed incident cases and the diagnosed prevalent cases of endometriosis by laparoscopy confirmation status into suspected cases without laparoscopy and confirmed cases with laparoscopy. The diagnosed prevalent cases of endometriosis are further segmented into stages as classified by the ASRM: stage I or minimal, stage II or mild, stage III or moderate, and stage IV or severe. Additionally, the diagnosed prevalent cases of endometriosis are segmented by phenotypes such as SUP, OMA, and DIE. The diagnosed prevalent cases of endometriosis are segmented by comorbidities such as CPP, dysmenorrhea, and dyspareunia.
- This epidemiology forecast for endometriosis is supported by data obtained from peer-reviewed articles and population-based studies. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the forecast diagnosed incident cases and diagnosed prevalent cases of endometriosis across these markets.
Reasons to Buy
The endometriosis epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global endometriosis market.
- Quantify patient populations in the global endometriosis market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for endometriosis therapeutics in each of the markets covered.
Table of Contents
Table of Contents
- About GlobalData
List of Tables
List of Figures
1 Endometriosis: Executive Summary
- 1.1 Catalyst
- 1.2 Related reports
- 1.3 Upcoming reports
2 Epidemiology
- 2.1 Disease background
- 2.2 Risk factors and comorbidities
- 2.3 Global and historical trends
- 2.4 7MM forecast methodology
- 2.4.1 Sources
- 2.4.2 Forecast assumptions and methods
- 2.4.3 Forecast assumptions and methods: diagnosed incident cases of endometriosis - 7MM
- 2.4.4 Forecast assumptions and methods: diagnosed prevalent cases of endometriosis
- 2.4.5 Forecast assumptions and methods: laparoscopy confirmation status for the diagnosed incident cases of endometriosis
- 2.4.6 Forecast assumptions and methods: laparoscopy confirmation status for the diagnosed prevalent cases of endometriosis
- 2.4.7 Forecast assumptions and methods: diagnosed prevalent cases of endometriosis by ASRM stage
- 2.4.8 Forecast assumptions and methods: diagnosed prevalent cases of endometriosis by phenotype
- 2.4.9 Forecast assumptions and methods: diagnosed prevalent cases of endometriosis by comorbidities
- 2.5 Epidemiological forecast for endometriosis (2024-34)
- 2.5.1 Diagnosed incident cases of endometriosis
- 2.5.2 Age-specific diagnosed incident cases of endometriosis
- 2.5.3 Laparoscopy confirmation status for the diagnosed incident cases of endometriosis
- 2.5.4 Diagnosed prevalent cases of endometriosis
- 2.5.5 Age-specific diagnosed prevalent cases of endometriosis
- 2.5.6 Laparoscopy confirmation status for the diagnosed prevalent cases of endometriosis
- 2.5.7 Diagnosed prevalent cases of endometriosis by ASRM stage
- 2.5.8 Diagnosed prevalent cases of endometriosis by phenotype
- 2.5.9 Diagnosed prevalent cases of endometriosis by comorbidities
- 2.6 Discussion
- 2.6.1 Epidemiological forecast insight
- 2.6.2 Limitations of the analysis
- 2.6.3 Strengths of the analysis
3 Appendix
- 3.1 Bibliography
- 3.2 About the authors
- 3.2.1 Epidemiologist
- 3.2.2 Reviewers
- 3.2.3 Vice President of Disease Intelligence and Epidemiology
- 3.2.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence
- Contact Us
List of Table
List of Tables
- Table 1: Summary of updated data types
- Table 2: Risk factors and comorbidities for endometriosis
List of Figure
List of Figures
- Figure 1: 7MM, diagnosed incident cases of endometriosis, women, N, ages 12-54 years, 2024 and 2034
- Figure 2: 7MM, diagnosed prevalent cases of endometriosis, women, N, ages 12-54 years, 2024 and 2034
- Figure 3: 7MM, diagnosed incidence of endometriosis (cases per 100,000 population), women, ages 12-54 years, 2024
- Figure 4: 7MM, diagnosed prevalence of endometriosis (%), women, ages 12-54 years, 2024
- Figure 5: 7MM, sources used and not used to forecast the diagnosed incident cases of endometriosis
- Figure 6: 7MM, sources used and not used to forecast the diagnosed prevalent cases of endometriosis
- Figure 7: 7MM, sources used to forecast the laparoscopy confirmation status for the diagnosed prevalent cases of endometriosis
- Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of endometriosis by ASRM stage
- Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of endometriosis by phenotype
- Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of endometriosis by comorbidities
- Figure 11: 7MM, diagnosed incident cases of endometriosis, N, women, ages 12-54 years, 2024
- Figure 12: 7MM, diagnosed incident cases of endometriosis by age, N, women, 2024
- Figure 13: 7MM, laparoscopy confirmation status for the diagnosed incident cases of endometriosis, N, women, ages 12-54 years, 2024
- Figure 14: 7MM, diagnosed prevalent cases of endometriosis, N, women, ages 12-54 years, 2024
- Figure 15: 7MM, diagnosed prevalent cases of endometriosis by age, N, women, 2024
- Figure 16: 7MM, laparoscopy confirmation status for the diagnosed prevalent cases of endometriosis, N, women, ages 12-54 years, 2024
- Figure 17: 7MM, diagnosed prevalent cases of endometriosis by ASRM stage, N, women, ages 12-54 years, 2024
- Figure 18: 7MM, diagnosed prevalent cases of endometriosis by phenotype, N, women, ages 12-54 years, 2024
- Figure 19: 7MM, diagnosed prevalent cases of endometriosis by comorbidities, N, women ages 12-54 years, 2024
